Performance evaluation of the SAMBA II SARS-CoV-2 test for point-of-care detection of SARS-CoV-2

Sonny M. Assennato, Allyson V. Ritchie, Cesar Nadala, Neha Goel, Cuijuan Tie, Lourdes M. Nadala, Hongyi Zhang, Rawlings Datir, Ravindra K. Gupta, Martin Curran, Helen H. Leea

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Nucleic acid amplification for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is the standard method for diagnosis. The majority of this testing is centralized and therefore has turnaround times of several days. Point-of-care (POC) testing with rapid turnaround times would allow more effective triage in settings where patient management and infection control decisions need to be made rapidly. The inclusivity and specificity of the Simple AMplification-Based Assay (SAMBA) II SARS-CoV-2 test were determined by both in silico analyses of the primers and probes and wet testing. The SAMBA II SARS-CoV-2 test was evaluated for performance characteristics. Clinical performance was evaluated in residual combined throat/nose swabs and compared to that of the Public Health England real-time PCR assay targeting the RdRp gene. The SAMBA II SARS-CoV-2 test has an analytical sensitivity of 250 copies/ml for detecting two regions of the genome (open reading frame 1ab [ORF1ab] and nucleocapsid protein [N]). The clinical performance was evaluated in 172 residual combined nose/throat swabs provided by the Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge (CMPHL), which showed an estimated positive percent agreement of 98.9% (95% confidence interval [CI], 93.83 to 99.97) and negative percent agreement of 96.4% (95% CI, 89.92 to 99.26) compared to testing by the CMPHL. The data show that the SAMBA II SARS-CoV-2 test performs equivalently to the centralized testing methods, but with a shorter turnaround time of 86 to 101 min. Point-of-care tests such as SAMBA should enable rapid patient management and effective implementation of infection control measures.

Original languageEnglish
Article numbere01262-20
JournalJournal of Clinical Microbiology
Volume59
Issue number1
DOIs
Publication statusPublished - Jan 2021
Externally publishedYes

Keywords

  • COVID-19
  • Point of care
  • SAMBA II
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Performance evaluation of the SAMBA II SARS-CoV-2 test for point-of-care detection of SARS-CoV-2'. Together they form a unique fingerprint.

Cite this